Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Phase 3

A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines

NCT06671483 · tracked via the Priya Life Science Germany tracker
Sponsor
Phase
Phase 3
Started
2025-03-03
Last updated
2026-11-12

Condition(s) studied

Psoriatic Arthritis

Investigational drug(s) / intervention(s)

Zasocitinib →Active ComparatorPlacebo

Zasocitinib: Zasocitinib over-encapsulated tablets.

Active Comparator: Active comparator capsule.

Placebo: Zasocitinib or active comparator matching placebo.

Study summary

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).

The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs.

The participants will be treated with either zasocitinib, active comparator, or placebo. Participants will be in the study for up to 60 weeks.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: Age: 1. The participant is aged 18 years or older at the time of signing the informed consent form (ICF). In South Korea, the age requirement for adult participants is \>=19 years of age. Disease Characteristics: 2. The participant has a diagnosis of PsA. 3. The participant must have signs and symptoms of PsA for at least 3 months prior to screening. 4. The participant meets the Classification Criteria for Psoriatic Arthritis (CASPAR criteria). 5. The participant has active arthritis as shown by a minimum of \>=3 tender joints in TJC68 and \>=3 swollen joints in SJC66 at the screening and baseline (Day 1) visits. 6. The participant has at least 1 active lesion of plaque PsO \>=2 cm in diameter, or any nail or nail bed changes characteristic of PsO. Medications for PsA: 7. The participant has had at least one of the following: 1. Inadequate response to a nonsteroidal anti-inflammatory drug (NSAID) (not applicable in the European Union \[EU\]/ European Economic Area \[EEA\]), OR 2. Inadequate response to a conventional synthetic disease-modifying antirheumatic drug (csDMARD). Exclusion Criteria: PsA and PsO: 1. The participant has other disease(s) that might confound the evaluations of benefit of zasocitinib therapy, including but not limited to rheumatoid arthritis, axial spondyloarthritis, systemic lupus erythematosus, Lyme disease, gout, or fibromyalgia. 2. The participant has a concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the study assessments, such as evidence of non-plaque PsO (erythrodermic, pustular, predominately guttate PsO, inverse, or drug-induced PsO).

Primary outcome measure(s)

  • Percentage of Participants Achieving American College of Rheumatology 20 (ACR20) Response at Week 16 for Zasocitinib Dose A and B Compared to Placebo — At Week 16
    ACR responses are the numerical measurement of improvement in multiple disease assessment criteria. It is a composite clinical outcome assessment (COA) measure that includes both clinician-reported outcome assessments (ClinROs) and patient-reported outcomes (PROs). An ACR20 response is defined as: greater than or equal to (\>=) 20 percent (%) improvement from baseline in both swollen joint count 66 joints (SJC66) and tender joint count 68 joints (TJC68), and \>=20% improvement from baseline in 3 of the following 5 assessments: Patient's global assessment (PtGA) of psoriatic arthritis (PsA) pain; PtGA of PsA; physician's global assessment of disease activity (PGA) of PsA; participant's assessment of physical function as measured by health assessment questionnaire-disability index (HAQ-DI); high-sensitivity C-reactive protein (hsCRP). Percentage of participants achieving ACR20 response at Week 16 for zasocitinib Dose A and B compared to placebo will be reported.

Trial sites (184)

FacilityCityRegionStatus
AARR- Chandler AZ Chandler Arizona
Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ Phoenix Arizona
Arizona Arthritis & Rheumatology Research, PLLC | Phoenix, AZ Phoenix Arizona
First OC Dermatology Research Inc. Fountain Valley California
Purushotham & Akther Kotha MD La Mesa California
Triwest Research Associates LLC La Mesa California
The Cohen Medical Centers Thousand Oaks California
Foothill Arthritis Clinic Tujunga California
Medvin Clinical Research Whittier California
Denver Arthritis Clinic | Denver, CO Denver Colorado
Arthritis & Rheumatic Disease Specialties (AARDS) Aventura Florida
RASF- Clinical Research Center Boca Raton Florida
Clinical Research of West Florida | Clearwater, FL Clearwater Florida
GNP Research, LLC | Hollywood, FL Cooper City Florida
Driven Research LLC Coral Gables Florida
Tectum Medical Research Davie Florida
Sweet Hope Research Specialty, Inc, d/b/a Neoclinical Research Hialeah Florida
Bioresearch Partners Miami Florida
HMD Research LLC Orlando Florida
Millennium Research | Ormond Beach, FL Ormond Beach Florida
IRIS Research and Development | Plantation, FL Plantation Florida
Sarasota Arthritis Research Center Sarasota Florida
West Broward Rheumatology Associates, Inc. Tamarac Florida
Clinical Research of West Florida | Tampa, FL Tampa Florida
Marietta Rheumatology Associates Marietta Georgia
GSCP/CIS Orland Park Illinois
Greater Chicago Specialty Physicians LLC/CIS Schaumburg Illinois
Accurate Clinical Research, Inc. | Lake Charles Lake Charles Louisiana
Klein & Associates, M.D., P.A. Hagerstown Maryland
Michigan Rheumatology Group, P.C. - Grand Blanc Office Grand Blanc Michigan
Ash Research Clinic - Howell Howell Michigan
June DO, PC Private Practice - Dr. Justus Fiechtner Lansing Michigan
Clinical Research Institute of Michigan Saint Clair Shores Michigan
Saint Louis Rheumatology St Louis Missouri
Albuquerque Center for Rheumatology PC Albuquerque New Mexico
Santa Fe Rheumatology Santa Fe New Mexico
NYU Langone Health | Joseph S. and Diane H. Steinberg Ambulatory Care Center - Rheumatology Department Brooklyn New York
Accellacare of Hickory Hickory North Carolina
University Hospitals | UH Cleveland Medical Center - Department of Medicine - Rheumatology Division Cleveland Ohio
Paramount Medical Research & Consulting, LLC Middleburg Heights Ohio

+ 144 more sites — see the full list on the official registry below.

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06671483 on ClinicalTrials.gov ↗ ← All trials in Germany